Brazil Patent Granted for RECCE Anti-Infectives
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has announced the granting of a patent in Brazil for its RECCE anti-infectives, which is a significant milestone for the company. The patent covers various aspects of the RECCE anti-infectives, including their preparation and use in treating a range of infections. This patent is part of Recce's strategy to expand its intellectual property portfolio in major antibiotic markets, with Brazil being a key focus. The CEO emphasized the importance of this patent in addressing the global challenge of antibiotic-resistant superbugs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- RCE Investor Webinar Presentation Deck
- Appendix 4D and Interim Financial Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- AUD $5.3m R&D Rebate Received
Later from Recce Pharmaceuticals
- Recce Signs Middle East Licensing Term Sheet
- Addendum to Recce Signs Middle East Licensing Term Sheet
- HREC Approval Accelerates Global Phase 3 DFI Strategy
- Placement & SPP to raise $8 million
- AUD $3.7M Income Tax Refund Received
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals